Effect of recombinant human transforming growth factor‐β2 dose on bone formation in rat femur titanium implant model
Source abstract
Abstract
Abstract Previously, we reported that application of 10 μg recombinant human TGF‐β2 (rhTGF‐β2) enhanced peri‐implant bone formation and bone‐implant contact in a rat model. To further investigate the dose effect, the present experiment evaluated doses of rhTGF‐β2 bracketed around 10 μg (5, 10, 20 μg) using the same model. Four groups (including buffer‐only control) received femoral implantation of hydroxyapatite/tricalcium phosphate‐coated titanium implants. Four weeks post‐surgery, all femurs were collected and analyzed by micro computed tomography followed by a mechanical test or histology. Compared with control, all rhTGF‐β2‐treated groups had significantly higher bone volume. Bone‐implant contact was not different between the control, 5, and 10 μg groups; however, the 20 μg group had less contact than the control. There were significant decreases in the strength of fixation in all rhTGF‐β2 treated groups compared with the control. In particular, while rhTGF‐β2 was able to enhance bone formation in the vicinity of the implant, the relative lack of bone‐implant contact in the 20 μg group depressed the strength of fixation, suggesting that the location as well as the amount of new bone formed is important for implant fixation. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Orthopaedic implants and arthroplasty · TGF-β signaling in diseases · Bone fractures and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 2005 National Hospital Discharge Survey
2. 10.1007/s00256005054110.1007/s002560050541 ↗
3. Roentgen stereophotogrammetric analysis as a predictor of mechanical loosening of knee prostheses10.1302/0301-620X.77B3.7744919 ↗
4. 10.2106/00004623-199508000-0000110.2106/00004623-199508000-00001 ↗
5. 10.1016/8756-3282(95)00324-710.1016/8756-3282(95)00324-7 ↗
6. 10.1002/jor.110014030310.1002/jor.1100140303 ↗
7. 10.3109/1745367960899776610.3109/17453679608997766 ↗
8. Transforming growth factor‐beta 1 stimulates bone ongrowth to weight‐loaded tricalcium phosphate coated implants: An experimental study in dogs10.1302/0301-620X.78B3.0780377 ↗
9. 10.1016/S0142-9612(00)00165-410.1016/S0142-9612(00)00165-4 ↗
10. 10.1016/j.orthres.2004.01.01010.1016/j.orthres.2004.01.010 ↗
11. 10.1016/S0736-0266(00)00015-210.1016/S0736-0266(00)00015-2 ↗
12. 10.1359/jbmr.2003.18.4.73010.1359/jbmr.2003.18.4.730 ↗
13. 10.1016/j.bone.2005.03.01110.1016/j.bone.2005.03.011 ↗
14. 10.1210/er.19.3.34910.1210/er.19.3.349 ↗
15. 10.1016/B978-012470862-4/50015-510.1016/B978-012470862-4/50015-5 ↗
16. 10.1016/j.bone.2007.10.00410.1016/j.bone.2007.10.004 ↗
17. 10.1083/jcb.110.6.219510.1083/jcb.110.6.2195 ↗
18. 10.1210/endo-124-6-299110.1210/endo-124-6-2991 ↗
19. 10.1002/jbmr.565005101310.1002/jbmr.5650051013 ↗
20. 10.1007/s00774005005710.1007/s007740050057 ↗
21. 10.1016/8756-3282(94)90300-X10.1016/8756-3282(94)90300-X ↗
22. 10.1210/er.2004-000110.1210/er.2004-0001 ↗
23. 10.1002/jbm.a.3006210.1002/jbm.a.30062 ↗
24. 10.1016/j.bone.2005.01.01910.1016/j.bone.2005.01.019 ↗
25. 10.1002/jbm.b.3029310.1002/jbm.b.30293 ↗
26. 10.1002/jbmr.565005080510.1002/jbmr.5650050805 ↗
27. 10.1210/endo-126-1-42110.1210/endo-126-1-421 ↗
28. 10.1002/jbmr.565009061110.1002/jbmr.5650090611 ↗
29. 10.1002/jcp.104140022510.1002/jcp.1041400225 ↗
30. 10.1002/jbmr.565008040610.1002/jbmr.5650080406 ↗
31. 10.1016/B978-012470862-4/50014-310.1016/B978-012470862-4/50014-3 ↗
32. 10.1083/jcb.132.1.19510.1083/jcb.132.1.195 ↗
33. 10.1007/s00223-004-0150-910.1007/s00223-004-0150-9 ↗
34. 10.1073/pnas.050741710210.1073/pnas.0507417102 ↗
35. Bone marrow regeneration after local injury: A review
36. 10.2106/JBJS.E.0084610.2106/JBJS.E.00846 ↗
37. 10.1002/jbm.a.3011510.1002/jbm.a.30115 ↗